You may also like

Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Read more
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline

Trending Articles

  1. Johnson & Johnson to spend up to $750m restructuring pharmaceutical supply chain The pharma giant is consolidating parts of its manufacturing network as it advances a $55bn US investment programme aimed at expanding domestic production of advanced medicines
  2. Sativex approved in Sweden For the treatment of spasticity due to multiple sclerosis
  3. Takara Bio extends biomanufacturing capabilities with custom enzyme manufacturing lab Its Gothenburg facility now has a manufacturing lab that can produce customised molecular biology products such as PCR and qPCR enzymes
  4. Leica Biosystems acquires StatLab to strengthen anatomic pathology and AI-enabled cancer diagnostics The deal adds StatLab's 50-year histology workflow portfolio to Leica Biosystems' computational pathology platform, supporting laboratory standardisation for AI-driven cancer diagnostics at scale
  5. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Manufacturing
Vacuubrand Vario® chemistry diaphragm pumps

Vacuubrand Vario® chemistry diaphragm pumps

The ideal solution for your laboratory
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Personal Protection
Ansell opens AXIS Portugal to accelerate PPE innovation in Europe

Ansell opens AXIS Portugal to accelerate PPE innovation in Europe

New immersive innovation hub near Coimbra combines safety training, product testing and collaborative R&D to support the future of workplace protection
Hi Tech Manufacturing
Gerresheimer significantly accelerates mould development in medical technology with “Digital Mold”

Gerresheimer significantly accelerates mould development in medical technology with “Digital Mold”

Linking the digital twin of the mould with production data. Virtual mould and process optimisation prior to physical construction Mould Lifecycle Management as the foundation for data analytics and AI applications in mould development and production
Subscribe now